Alan D. Marmorstein

Dr. Alan D. Marmorstein

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
AJAdiv A. Johnson
Adiv A. Johnson
KGKarina E. Guziewicz
Karina E. Guziewicz
CLC. Justin Lee
C. Justin Lee
RKRavi C. Kalathur
Ravi C. Kalathur
JPJose S. Pulido
Jose S. Pulido
AMAlan D. Marmorstein
Alan D. Marmorstein

1 February 2018 in Acta Biomaterialia
Verified
Journal Article
Closed access
JGJarel K. Gandhi
Jarel K. Gandhi
ZMZahid Manzar
Zahid Manzar
LBLori A. Bachman
Lori A. Bachman
CACynthia Andrews-Pfannkoch
Cynthia Andrews-Pfannkoch
TKTravis Knudsen
Travis Knudsen
AMAlan D. Marmorstein
Alan D. Marmorstein

1 July 2015 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
AJAdiv A. Johnson
Adiv A. Johnson
LBLori A. Bachman
Lori A. Bachman
BGBenjamin J. Gilles
Benjamin J. Gilles
SCSamuel D. Cross
Samuel D. Cross
KSKimberly E. Stelzig
Kimberly E. Stelzig
AMAlan D. Marmorstein
Alan D. Marmorstein
Purpose: Mutations in BEST1, encoding bestrophin-1 (Best1), cause autosomal recessive bestrophinopathy (ARB). Encoding bestrophin-1 is a pentameric anion channel localized to the basolateral plasma membrane of the RPE. Here, we characterize the effects of the mutations R141H (CGC > CAC) and I366fsX18 (c.1098_1100+7del), identified in a patient in our practice, on Best1 trafficking, oligomerization, and channel activity. Methods: Currents of Cl− were assessed in transfected HEK293 cells using whole-cell patch clamp. Best1 localization was assessed by confocal microscopy in differentiated, human-induced pluripotent stem cell-derived RPE (iPSC-RPE) cells following expression of mutants via adenovirus-mediated gene transfer. Oligomerization was evaluated by coimmunoprecipitation in iPSC-RPE and MDCK cells. Results: Compared to Best1, Best1I366fsX18 currents were increased while Best1R141H Cl− currents were diminished. Coexpression of Best1R141H with Best1 or Best1I366fsX18 resulted in rescued channel activity. Overexpressed Best1, Best1R141H, and Best1I366fsX18 were all properly localized in iPSC-RPE cells; Best1R141H and Best1I366fsX18 coimmunoprecipitated with endogenous Best1 in iPSC-RPE cells and with each other in MDCK cells. Conclusions: The first 366 amino acids of Best1 are sufficient to mediate channel activity and homo-oligomerization. The combination of Best1 and Best1R141H does not cause disease, while Best1R141H together with Best1I366fsX18 causes ARB. Since both combinations generate comparable Cl− currents, this indicates that ARB in this patient is not caused by a loss of channel activity. Moreover, Best1I366fsX18 differs from Best1 in that it lacks most of the cytosolic C-terminal domain, suggesting that the loss of this region contributes significantly to the pathogenesis of ARB in this patient.

13 January 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JGJarel K Gandhi
Jarel K Gandhi
FMFukutaro Mano
Fukutaro Mano
RIRaymond Iezzi
Raymond Iezzi
SLStephen A LoBue
Stephen A LoBue
BHBrad H Holman
Brad H Holman
AMAlan D. Marmorstein
Alan D. Marmorstein
Retinal pigment epithelium (RPE) transplantation for the treatment of macular degeneration has been studied for over 30 years. Human clinical trials have demonstrated that RPE monolayers exhibit improved cellular engraftment and survival compared to single cell suspensions. The use of a scaffold facilitates implantation of a flat, wrinkle-free, precisely placed monolayer. Scaffolds currently being investigated in human clinical trials are non-degradable which results in the introduction of a chronic foreign body. To improve RPE transplant technology, a degradable scaffold would be desirable. Using human fibrin, we have generated scaffolds that support the growth of an RPE monolayer in vitro. To determine whether these scaffolds are degraded in vivo, we developed a surgical approach that delivers a fibrin hydrogel implant to the sub-retinal space of the pig eye and determined whether and how fast they degraded. Using standard ophthalmic imaging techniques, the fibrin scaffolds were completely degraded by postoperative week 8 in 5 of 6 animals. Postmortem histologic analysis confirmed the absence of the scaffold from the subretinal space at 8 weeks, and demonstrated the reattachment of the neurosensory retina and a normal RPE–photoreceptor interface. When mechanical debridement of a region of native RPE was performed during implantation surgery degradation was accelerated and scaffolds were undetectable by 4 weeks. These data represent the first in situ demonstration of a fully biodegradable scaffold for use in the implantation of RPE and other cell types for treatment of macular degeneration and other retinal degenerative diseases.

14 March 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAlan D. Marmorstein
Alan D. Marmorstein
AJAdiv A. Johnson
Adiv A. Johnson
LBLori A. Bachman
Lori A. Bachman
CACynthia Andrews-Pfannkoch
Cynthia Andrews-Pfannkoch
TKTravis Knudsen
Travis Knudsen
JPJose S. Pulido
Jose S. Pulido
Autosomal recessive bestrophinopathy (ARB) is caused by mutations in the gene BEST1 which encodes bestrophin 1 (Best1), an anion channel expressed in retinal pigment epithelial (RPE) cells. It has been hypothesized that ARB represents the human null phenotype for BEST1 and that this occurs due to nonsense mediated decay (NMD). To test this hypothesis, we generated induced pluripotent stem cells (iPSCs) from a patient with ARB and her parents. After differentiation to retinal pigment epithelial (iPSC-RPE) cells, both BEST1 mRNA and Best1 protein expression were compared to controls. BEST1 mRNA expression levels, determined by quantitative PCR, were similar in ARB iPSC-RPE, parental cells, and genetically unrelated controls. Western blotting revealed that CRALBP and RPE65 were expressed within the range delineated by unrelated controls in iPSC-RPE from the ARB donor and her parents. Best1 protein was detected in different clones of ARB iPSC-RPE, but at reduced levels compared to all controls. When tested for the ability to phagocytose photoreceptor outer segments, ARB iPSC-RPE exhibited impaired internalization. These data suggest that impaired phagocytosis is a trait common to the bestrophinopathies. Furthermore, ARB is not universally the result of NMD and ARB, in this patient, is not due to the absence of Best1.

27 April 2016 in Ophthalmic Genetics
Verified
Journal Article
Closed access
LDLauren A. Dalvin
Lauren A. Dalvin
JPJose S. Pulido
Jose S. Pulido
AMAlan D. Marmorstein
Alan D. Marmorstein
Background: Vitelliform dystrophies are a group of macular degenerative diseases characterized by round yellow lesions in the macula. While often idiopathic, vitelliform dystrophies include inherited maculopathies such as Best disease and some cases of pattern dystrophy. The prevalence of vitelliform dystrophies in the United States has not been reported. This study examined the prevalence of vitelliform dystrophies in Olmsted County, Minnesota. Materials and methods: The Rochester Epidemiology Project database was used to identify all cases of vitelliform or pattern dystrophy in Olmsted County from 1 January 2000–31 December 2014. Results: Overall, 27 patients had true vitelliform lesions, indicating a prevalence of 1 in 5500. Of these, two had genetically confirmed Best disease, and an additional five to seven carried a diagnosis of Best disease, which chart reviews confirmed as probable cases; 18–20 patients had adult-onset vitelliform macular dystrophy. The prevalence of Best disease was 1 in 16,500 to 1 in 21,000. Adult-onset vitelliform macular dystrophy was found in 1 in 7400 to 1 in 8200. Conclusions: Vitelliform dystrophies affect 1 in 5500 individuals in Olmsted County. While the values in this study provide good estimates for the prevalence of Best disease versus adult-onset vitelliform macular dystrophy, the results are limited by dependence on diagnoses made by other ophthalmologists and underutilization of genetic testing. Thus, these diseases should be thought of as at least as prevalent as reported here. As therapies for Best disease and other macular degenerative diseases are quickly becoming a reality, genetic testing should be employed as the gold standard for diagnosis of these diseases.